Tenet Healthcare Corp (THC) · Oct 29, 2026 · Earnings
Beat — Adjusted EPS $6.64 vs ~$4.68 consensus; revenue $5.631B vs ~$5.49B
Tenet’s Q3 earnings beat consensus and the company raised 2026 EBITDA and free-cash-flow guidance, though transition timing inflated the quarter.
Tenet is executing a two-part healthcare strategy: expanding its higher-margin ambulatory surgery platform while improving hospital utilization and cost control. The quarter advances that story, but the headline result includes a sizable revenue-cycle transition timing benefit.
The quarter cleared a high earnings bar. Adjusted diluted EPS was $6.64 versus about $4.68 consensus, while net operating revenue was $5.631 billion versus roughly $5.49 billion expected. That is a clear beat, not merely a favorable comparison with last year. Q3 adjusted EBITDA reached $1.355 billion, up 23.3% year over year, and the company raised full-year adjusted EBITDA guidance by $195 million at the midpoint.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Adjusted diluted EPS (Financial Highlights) | $6.64 | $3.70 | ~$4.68 |
| Net operating revenues (Financial Highlights) | $5.631B | $5.289B | ~$5.49B |
| Adjusted EBITDA (Financial Highlights) | $1.355B | $1.099B | |
| Adjusted EBITDA margin (Segment results) | 24.1% | 20.8% | |
| Adjusted free cash flow (Cash Flow reconciliation) | $1.102B | $781M |
Underlying operations were good, especially in hospitals, but not uniformly volume-led. Hospital adjusted EBITDA rose to $818 million from $607 million, with admissions up 2.8% and adjusted admissions up 3.2%. Ambulatory revenue increased 7.5% and EBITDA rose 9.1%, but surgical cases fell 1.5%; most of the ambulatory revenue growth came from a 6.1% increase in revenue per case rather than more procedures. 〔0〕
The main quality caveat is the $147 million Q3 EBITDA lift from the Conifer transition. Tenet recognized a $97 million timing-related revenue adjustment and about $50 million of transition efficiencies as the CommonSpirit revenue-cycle-services handoff moved faster than previously scheduled. Management says this does not change full-year contract-termination or revenue expectations, but it does make Q3 reported profitability look stronger than the recurring run rate.
Guidance was raised on more than the one-time accounting item. Full-year adjusted EBITDA is now guided to $5.05 billion–$5.20 billion, and adjusted free cash flow to $2.825 billion–$3.125 billion, with the company pointing to sustained same-facility revenue growth and expense discipline. The raise is therefore a meaningful upgrade to the operating story, although payer mix and weaker procedure volumes remain visible offsets.
Bottom line: Tenet delivered a genuine earnings beat and raised its cash-generation outlook, strengthening the case that its margin and ambulatory strategy is working. The result is materially better than expected, but the Q3 headline is partly flattered by a $147 million transition-related benefit that will not repeat in the same form.
Q4 report and initial FY 2027 outlook
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!